Skip to main content

AV graft lesions across the elbow

Not indicated for use in Canada.

Endovascular management of lesions at points of flexion that require stenting is challenging:

  • Stent grafts must be able to conform to the anatomy to provide thorough range of motion and be durable to resist fractures.
  • Flexion points in the circuit outside of the elbow are often underappreciated.
    • Positional studies highlight points of flexion outside of the elbow.1

The GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface* is engineered for long-term performance in areas of flexion:

Proven Patency

  • When placed across the elbow: 
    • 72% target lesion six-month primary patency.2
    • 67% circuit six-month primary patency.2 
durability and flexibility statistics

Demonstrated durability 

  • 83% access secondary patency and zero device fractures at two years when placed across the elbow.3
  • The VIABAHN® Device has a reported fracture rate of .003% across all uses. (Data on file 2018; W. L. Gore & Associates, Inc.; Flagstaff, AZ.)

Conformable yet durable design

  • Like with all Gore single nitinol wire stents, the design and frame construction reduces strain to provide mechanical durability.
  • Proven flexibility maintains flow at points of flexion.1

The [GORE® VIABAHN® Endoprosthesis] has the flexibility, durability, and the indication to successfully treat lesions across the antecubital fossa. In my experience, the device does not compress or kink when the extremity is flexed as compared with other stent grafts…

-William DaVanzo, M.D.

AV access maintenance challenges

  • The GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface has proven success in the most challenging AV access cases, including early PTA failures, lesions at points of flexion, and in thrombosed grafts.

Learn more.

Connect with a Gore Field Sales Associate

* As used by Gore, Heparin Bioactive Surface refers to Gore’s proprietary CBAS® Heparin Surface.

† Also referred to as the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface in some regions.

  1. Webb M.  Flow disturbances of upper arm graft outflow uncovered by positional studies.  Endovascular Today 2014;13(6)Supplement:31-33.
  2. Vesely T, DaVanzo W, Behrend T, Dwyer A, Aruny J. Balloon angioplasty versus Viabahn stent graft for treatment of failing or thrombosed prosthetic hemodialysis grafts. Journal of Vascular Surgery 2016;64(5):1400-1410.e1.
  3. W. L. Gore & Associates, Inc. GORE® VIABAHN® Endoprosthesis versus Percutaneous Transluminal Angioplasty (PTA) to Revise Arteriovenous Grafts at the Venous Anastomosis in Hemodialysis Patients. (GORE REVISE Study, AVR 06-01). Flagstaff, AZ: W. L. Gore & Associates, Inc; 2012. [IDE Final Clinical Study Report]. G070069.
  4. GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface Instructions for Use (IFU). W. L. Gore & Associates, Inc. Accessed February 8, 2023.

Refer to Instructions for Use at for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

eIFU Symbol